Tyrosine kinase 2 - Wikipedia Tyrosine kinase 2 Non-receptor tyrosine-protein kinase TYK2 is an enzyme that in humans is encoded by the TYK2 gene [5][6] TYK2 was the first member of the JAK family that was described (the other members are JAK1, JAK2, and JAK3) [7] It has been implicated in IFN-α, IL-6, IL-10 and IL-12 signaling
Tyrosine Kinase inhibitors (TKIs): Uses Side Effects Tyrosine kinase inhibitors treat a wide range of cancers and cause an equally wide range of side effects For example, one group of tyrosine kinase inhibitors targets cancers such as non-small lung cancer, breast, colorectal and pancreatic cancer
TYK2: an emerging therapeutic target in rheumatic disease Tyrosine kinase 2 (TYK2), a Janus kinase family member, is involved in immune signalling and is implicated in autoimmune diseases such as systemic lupus erythematosus; inhibitors of TYK2 show
Tyrosine kinase inhibitors: Multi-targeted or single-targeted? Both multi-kinase inhibitors and single-kinase inhibitors have advantages and disadvantages, which are related to potential resistance mechanisms, pharmacokinetics, selectivity and tumor environment In different malignancies various tyrosine kinases are mutated or overexpressed and several resistance mechanisms exist
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data . . . Takeda today announced positive topline results for the two pivotal Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO) The studies demonstrated superiority of zasocitinib compared to
ErbB-1 ErbB-2 tyrosine kinase-IN-1 - MedChemExpress ErbB-1 ErbB-2 tyrosine kinase-IN-1 is a dual ErbB-1 ErbB-2 tyrosine kinase inhibitor with IC50 values of 0 027 μM and 0 026 μM ErbB-1 ErbB-2 tyrosine kinase-IN-1 targets the ATP binding region of ErbB-1 and ErbB-2 tyrosine kinases
Tyrosine Kinase 2 Inhibitor Benefits AD in Phase 2 Study ICP-332, an investigational tyrosine kinase 2 inhibitor, demonstrated favorable safety and resulted in more than a 70% reduction in Eczema Area and Severity Index (EASI) scores in a randomized